Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JL, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V et al on behalf of the KEYNOTE-716 Investigators.
Lancet 2022; 399: 1718-1729.
Adjuvant treatment with pembrolizumab every three weeks for up to 17 cycles was examined in the study that included 976 patients with median follow-up of 20.9 months. Treatment improved recurrence-free survival: 85 versus 76%, hazard ratio 0.61, 95 per cent confidence interval 0.45 to 0.82.
Comment: This difference is valuable, but again, it remains to be seen how late outcomes are affected.
17 May 2022Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.